Cabaletta Bio, Inc. (CABA)

Cabaletta Bio, Inc. (CABA) Healthcare & Pipeline Overview

Cabaletta Bio, Inc. pioneers CAAR T-cell therapies targeting B cell-mediated autoimmune diseases, including mucosal pemphigus vulgaris and Hemophilia A. Their innovative approach selectively eliminates pathogenic B cells, differentiating them in the competitive biotechnology landscape focused on autoimmune disease treatment.

What Is the Investment Thesis for CABA?

Cabaletta Bio's investment thesis centers on its innovative CAAR T-cell technology and its potential to revolutionize the treatment of B cell-mediated autoimmune diseases. The company's lead candidate, DSG3-CAART, is in Phase 1 clinical trials, offering early-stage validation of the platform. Successful clinical trial outcomes and regulatory approvals could drive significant value. Key value drivers include the expansion of the CAAR T-cell platform to address additional autoimmune indications and strategic partnerships to accelerate development and commercialization. A potential risk factor is the inherent uncertainty in clinical trials and regulatory approval processes. The company's market capitalization is $0.33B as of 2026-05-09.

Based on FMP financials and quantitative analysis

CABA Key Highlights

• Cabaletta Bio is pioneering CAAR T-cell therapy, a novel approach to treating B cell-mediated autoimmune diseases.
• DSG3-CAART, the lead product candidate, is currently in Phase I clinical trials for mucosal pemphigus vulgaris and Hemophilia A with Factor VIII alloantibodies.
• The company has a strategic collaboration with the University of Pennsylvania, enhancing its research and development capabilities.
• Cabaletta Bio's pipeline includes preclinical and discovery stage products targeting myasthenia gravis and additional pemphigus vulgaris subtypes.
• The company's market capitalization is $0.33B as of 2026-05-09.

Who Are CABA's Competitors?

CABA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CABA's Key Strengths?

• Proprietary CAAR T-cell technology platform
• Focus on a specific subset of autoimmune diseases
• Strategic collaborations with leading academic institutions
• Experienced management team

What Are CABA's Weaknesses?

• Early-stage clinical development
• Limited financial resources
• Dependence on a single technology platform
• High regulatory hurdles

What Could Drive CABA Stock Higher?

• Data readout from Phase I clinical trial of DSG3-CAART for mucosal pemphigus vulgaris.
• Initiation of clinical trials for MuSK-CAART in myasthenia gravis.
• Continued development of FVIII-CAART for Hemophilia A.
• Expansion of CAAR T-cell platform to new autoimmune indications.

What Are the Key Risks for CABA?

• Financial-distress signal — its Altman Z-Score of -1.54 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory hurdles and delays in approval processes.
• Competition from established pharmaceutical companies.
• Patent challenges and intellectual property disputes.
• Dependence on a single technology platform.

What Are the Growth Opportunities for CABA?

• Expansion of DSG3-CAART Clinical Trials: Cabaletta Bio has the opportunity to expand the clinical development of DSG3-CAART to additional indications beyond mucosal pemphigus vulgaris and Hemophilia A. This includes exploring its potential in other autoimmune blistering diseases and related conditions. Successful clinical trials in these new indications could significantly broaden the market opportunity for DSG3-CAART and increase its commercial potential. The timeline for this expansion is dependent on the progress of ongoing Phase I trials and regulatory approvals.
• Advancement of MuSK-CAART Program: The preclinical MuSK-CAART program represents a significant growth opportunity for Cabaletta Bio. Myasthenia gravis, the target of this program, is a serious autoimmune disease with a substantial patient population. Advancing MuSK-CAART into clinical trials and demonstrating its safety and efficacy could lead to a valuable new therapy for patients with myasthenia gravis. The timeline for this advancement is dependent on preclinical data and regulatory approvals for clinical trials.
• Development of FVIII-CAART for Hemophilia A: Cabaletta Bio's FVIII-CAART program targets a subset of patients with Hemophilia A who develop Factor VIII alloantibodies, a significant complication of treatment. Successful development of FVIII-CAART could provide a novel therapeutic option for these patients, improving their quality of life and reducing the burden of their disease. The timeline for this development is dependent on preclinical research and regulatory approvals.
• Expansion of CAAR T-Cell Platform: Cabaletta Bio can leverage its CAAR T-cell platform to develop therapies for additional B cell-mediated autoimmune diseases. This includes exploring new targets and indications beyond the current pipeline. The expansion of the platform could create a pipeline of novel therapies and establish Cabaletta Bio as a leader in CAAR T-cell technology. The timeline for this expansion is dependent on research and development efforts and regulatory approvals.
• Strategic Partnerships and Collaborations: Cabaletta Bio can pursue strategic partnerships and collaborations to accelerate the development and commercialization of its CAAR T-cell therapies. This includes partnering with pharmaceutical companies, academic institutions, and other biotechnology companies. These partnerships could provide access to additional resources, expertise, and funding, accelerating the progress of Cabaletta Bio's pipeline. The timeline for these partnerships is dependent on business development efforts and market opportunities.

What Opportunities Does CABA Have?

• Expansion of CAAR T-cell platform to new indications
• Strategic partnerships with pharmaceutical companies
• Increasing prevalence of autoimmune diseases
• Advancements in cell therapy technology

What Threats Does CABA Face?

• Competition from established pharmaceutical companies
• Regulatory delays
• Clinical trial failures
• Patent challenges

What Are CABA's Competitive Advantages?

• Proprietary CAAR T-cell technology platform.
• Strong intellectual property protection for CAAR T-cell therapies.
• First-mover advantage in the development of CAAR T-cell therapies for autoimmune diseases.
• Strategic collaborations with leading academic institutions.

What Does CABA Do?

Cabaletta Bio, Inc., founded in 2017 and headquartered in Philadelphia, Pennsylvania, is a clinical-stage biotechnology company dedicated to discovering and developing engineered T cell therapies for patients suffering from B cell-mediated autoimmune diseases. The company's core technology revolves around chimeric autoantibody receptor (CAAR) T cells. These engineered cells are designed to selectively bind to and eliminate B cells responsible for producing disease-causing autoantibodies or pathogenic B cells. Cabaletta Bio's lead product candidate, DSG3-CAART, is currently in Phase I clinical trials for the treatment of mucosal pemphigus vulgaris, a debilitating autoimmune blistering skin disease. Additionally, DSG3-CAART is being investigated for Hemophilia A with Factor VIII alloantibodies. The company's pipeline also includes MuSK-CAART, a preclinical stage product targeting myasthenia gravis; FVIII-CAART, a discovery stage product for Hemophilia A; and DSG3/1-CAART, a discovery stage product for mucocutaneous pemphigus vulgaris. Cabaletta Bio collaborates with the University of Pennsylvania and has a research agreement with The Regents of the University of California, further strengthening its research and development capabilities. Formerly known as Tycho Therapeutics, Inc., the company rebranded as Cabaletta Bio, Inc. in August 2018, marking a pivotal step in its evolution towards becoming a leader in CAAR T-cell therapy.

What Products and Services Does CABA Offer?

• Develop engineered T cell therapies for autoimmune diseases.
• Utilize CAAR T-cell technology to target and eliminate pathogenic B cells.
• Conduct clinical trials to evaluate the safety and efficacy of CAAR T-cell therapies.
• Focus on B cell-mediated autoimmune diseases, such as mucosal pemphigus vulgaris and myasthenia gravis.
• Research and develop new CAAR T-cell therapies for additional autoimmune indications.
• Collaborate with academic institutions and other organizations to advance research and development efforts.

How Does CABA Make Money?

• Develop and commercialize CAAR T-cell therapies for autoimmune diseases.
• Generate revenue through sales of approved therapies.
• Establish partnerships and collaborations to accelerate development and commercialization.
• Receive funding through venture capital, public offerings, and grants.

What Industry Does CABA Operate In?

Cabaletta Bio operates within the rapidly evolving biotechnology industry, specifically targeting the autoimmune disease market. This market is characterized by a high unmet need for effective and targeted therapies. The competitive landscape includes companies developing traditional biologics, small molecules, and other cell-based therapies. Cabaletta Bio's CAAR T-cell technology offers a differentiated approach by selectively eliminating pathogenic B cells, potentially providing a more durable and targeted treatment option compared to existing therapies. The autoimmune disease market is projected to continue growing, driven by increasing prevalence and advancements in diagnostic capabilities.

Who Are CABA's Key Customers?

• Patients with B cell-mediated autoimmune diseases.
• Healthcare providers who treat autoimmune diseases.
• Hospitals and clinics that administer CAAR T-cell therapies.
• Pharmaceutical companies and other organizations that partner with Cabaletta Bio.

Net buyingInsider Activity

Over the past six months, Cabaletta Bio, Inc. insiders filed 19 SEC Form 4 transactions — 0 sales and 19 purchases. On net that is roughly 1.9M shares acquired (about $6.3M) — insiders putting money in tends to read as conviction.

CABA Valuation & Market Position

With a $497.32M market cap, Cabaletta Bio, Inc. sits in the small-cap segment of the market. Relative to its peer group, CABA's quantitative score of 22/100 is below the peer average of 76/100.

Key Financial Metrics

Its free cash flow yield is -29.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -51.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Cabaletta Bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.54 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cabaletta Bio, Inc. revenue of about $2.5M for fiscal 2026, with EPS near $-1.37. The estimate reflects 6 contributing analysts.

Company Profile

Cabaletta Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Philadelphia, US. The company is led by CEO Steven A. Nichtberger. CABA has traded publicly since 2019.

CABA Financials

CABA Latest News

CABA Analyst Consensus

CABA MoonshotScore

Latest Cabaletta Bio, Inc. Analysis

What Investors Ask About Cabaletta Bio, Inc. (CABA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources